ライフサイエンスコーパス: thrombolysis

1 logical, life-threatening clots and thrombi (thrombolysis).

2 o randomisation, stroke-related factors, and thrombolysis.

3 e ischemic stroke who receive intra-arterial thrombolysis.

4 cological target of human ischemic stroke is thrombolysis.

5 eatment by mechanical thrombectomy and/or IA thrombolysis.

6 e onset within 4.5 hours, the time window of thrombolysis.

7 nts with an ischemic stroke are eligible for thrombolysis.

8 lications for the assessment and delivery of thrombolysis.

9 of onset have been previously excluded from thrombolysis.

10 ution of thrombosis during catheter-directed thrombolysis.

11 on HT subtypes and outcome after intravenous thrombolysis.

12 mes in patients with mild stroke who receive thrombolysis.

13 tibility-weighted imaging before intravenous thrombolysis.

14 pannus and thrombus, the latter amenable to thrombolysis.

15 nd may therefore be potentially suitable for thrombolysis.

16 on making were both associated with desiring thrombolysis.

17 itive, and 2731 (38.5%) received intravenous thrombolysis.

18 from ultrasound-assisted, catheter-directed thrombolysis.

19 cal processes controlling different steps of thrombolysis.

20 for ultrasound-facilitated catheter-directed thrombolysis.

21 R) estimates lesion age to guide intravenous thrombolysis.

22 e impaired CA (32% vs. 62%, p = 0.02) during thrombolysis.

23 lowing ultrasound-assisted catheter-directed thrombolysis.

24 either Definity or OFP t-ELIP enhances rt-PA thrombolysis.

25 0.86 (0.81 to 0.91) and 0.85 (0.81 to 0.90); thrombolysis 0.85 (0.75 to 0.97) and 0.85 (0.75 to 0.97)

26 OR] = 0.21; 95% CI, 0.18-0.24), lower use of thrombolysis (12% vs 19% of those with ischemic stroke;

27 .7% [10 of 44] vs. 0% [0 of 92]), and failed thrombolysis (18.2% [8 of 44] vs. 4.3% [3 of 92]; p = 0.

28 1 minutes]) and from the door to intravenous thrombolysis (32 minutes [IQR, 24-47 minutes]) were sign

29 Rates of golden hour thrombolysis, 7- and 90-day mortality, secondary intrace

30 ng adjusted OR: 0.61; 95% CI: 0.60 to 0.62) (thrombolysis adjusted OR: 0.80; 95% CI: 0.78 to 0.82).

31 Thrombolysis administration in Tyrol increased after pro

32 r comprehensive stroke management programme, thrombolysis administration increased and clinical outco

33 an states without similar stroke programmes, thrombolysis administration remained stable or declined

34 , admission to stroke unit (day 0 or 1), and thrombolysis administration.

35 Thrombolysis also benefits selected patients with eviden

36 e Scale score >=10) who received intravenous thrombolysis (alteplase bolus) within 3 h of symptom ons

37 istently report a reduction in delays before thrombolysis and cause-based triage in regard to the app

38 with rapid reperfusion by use of intravenous thrombolysis and endovascular thrombectomy shown to redu

39 ocuses on rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy, which both r

40 anticoagulation, while interventions such as thrombolysis and inferior vena cava filters are reserved

41 d to identify studies addressing the role of thrombolysis and mechanical thrombectomy in acute stroke

42 formed in 144 and 146 patients randomized to thrombolysis and placebo, respectively) did not reveal s

43 evels, and the development and timely use of thrombolysis and stents in acute coronary syndrome to li

44 Thrombolysis and stroke units are accepted as standards

45 nhibits tissue plasminogen activator-induced thrombolysis and subsequent reduction of ischemic brain

46 literature, we propose new ways to approach thrombolysis and suggest potential prophylactic and ther

47 o block tissue plasminogen activator-induced thrombolysis and to obtain neuroprotection and inhibitio

48 ecanalization of the occluded artery through thrombolysis and/or endovascular thrombectomy is restric

49 ve reperfusion therapies, either intravenous thrombolysis and/or mechanical thrombectomy.

50 n off-hours pattern (door-to-needle time for thrombolysis), and a flow pattern whereby quality change

51 diate thrombectomy for LVO after intravenous thrombolysis, and (c) CT angiography for all and best me

52 d, of whom 157 were eligible for intravenous thrombolysis, and 104 patients were enrolled.

53 te, secondary intracerebral hemorrhage after thrombolysis, and 7-day mortality.

54 Previous ICrH, thrombolysis, and male sex affected the risk, whereas an

55 reased the risk of PH 24 h after intravenous thrombolysis, and predicted poor clinical outcome indepe

56 efit of tissue plasminogen activator-induced thrombolysis; and 2) could be an efficient neuroprotecti

57 on in humans, particularly in the setting of thrombolysis, are warranted.

58 ng-term follow-up, 65 deaths occurred in the thrombolysis arm and 53 occurred in the placebo arm.

59 sessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placeb

60 including time to neuroimaging and rates of thrombolysis, as well as outcomes, including death and d

61 ian NIHSS of 6.5 (range, 2-24), and received thrombolysis at a mean time of 10.3 +/- 2.6 LSN and 2.6

62 ase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST), we aimed to assess the efficacy a

63 ients with stroke cannot receive intravenous thrombolysis because the time of symptom onset is unknow

64 patients (71%) were treated with intravenous thrombolysis before IA therapy.

65 ur patterns of variation: a diurnal pattern (thrombolysis, brain scan within 12 h, brain scan within

66 tion tube is more advantageous for efficient thrombolysis by enhancing cavitation-induced microstream

67 armaco-mechanical device designed to enhance thrombolysis by increasing the exposure of thrombus to e

68 oped a reaction-diffusion-advection model of thrombolysis by tissue plasminogen activator (TPA) in an

69 ation of NIHSS is higher in patients who are thrombolysis candidates.

70 ) or anticoagulation plus pharmacomechanical thrombolysis (catheter-mediated or device-mediated intra

71 The use of catheter-directed thrombolysis (CDT) in the treatment of acute proximal lo

72 ctice patterns and role of catheter-directed thrombolysis (CDT) in the treatment of inferior vena cav

73 y, type of intervention (angioplasty, stent, thrombolysis), clinical location (hospital outpatient vs

74 -needle (DTN) times </=60 minutes for stroke thrombolysis, critical DTN process failures persist.

75 d that physicians should not presume to make thrombolysis decisions for incapacitated patients with a

76 us medical management, including intravenous thrombolysis, demonstrated strong positive data in suppo

77 Compared with thrombolysis during control weeks, there was a reduction

78 ter symptom onset using standard intravenous thrombolysis eligibility criteria.

79 orial, open-label, blinded-endpoint trial of thrombolysis-eligible patients (age >=18 years) with acu

80 Golden hour thrombolysis entails no risk to the patients' safety and

81 Thrombolysis for acute ischemic stroke in the unwitnesse

82 The slow progress in thrombolysis for acute stroke has been multifactorial.

83 lly invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a

84 Intravenous thrombolysis for ischaemic stroke remains underused worl

85 among patients undergoing catheter-directed thrombolysis for submassive or massive pulmonary embolis

86 nd 96% in the conventional catheter-directed thrombolysis group (P = 0.33), and there was no differen

87 /- 27% in the conventional catheter-directed thrombolysis group (P = 0.91).

88 otic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ra

89 in the ultrasound-assisted catheter-directed thrombolysis group and 54% +/- 27% in the conventional c

90 low-up period (12% in the pharmacomechanical-thrombolysis group and 8% in the control group, P=0.09).

91 in the ultrasound-assisted catheter-directed thrombolysis group and 96% in the conventional catheter-

92 yndrome were lower in the pharmacomechanical-thrombolysis group than in the control group at 6, 12, 1

93 in 18% of patients in the pharmacomechanical-thrombolysis group versus 24% of those in the control gr

94 HT regions after intra-arterial thrombolysis had lower permeability values on K(trans) m

95 treatment, patients who received golden hour thrombolysis had no higher risks for 7- or 90-day mortal

96 Although the field of acute thrombolysis has been making progress slowly for many ye

97 Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical thrombolysis

98 mage is the major risk factor for fatal post-thrombolysis ICH, but rapidly assessing BBB damage befor

99 ut maneuver in 9 cases (success rate, 100%), thrombolysis in 9 patients (success rate, 56%), and pump

100 e indicator for efficient use of intravenous thrombolysis in acute ischemic stroke (AIS).

101 The effectiveness of intravenous thrombolysis in acute ischemic stroke is time dependent.

102 specially in light of the severe underuse of thrombolysis in acute ischemic stroke.

103 CI = 0.84-0.94), a lower chance of modified Thrombolysis in Cerebral Infarction (mTICI) grade 2b to

104 kin Score (mRs) 0-2, recanalisation success (thrombolysis in cerebral infarction (TICI) >=2b) and sym

105 while reperfusion was assessed by using the Thrombolysis in Cerebral Infarction (TICI) scale.

106 with achievement of substantial reperfusion (Thrombolysis in Cerebral Infarction [TICI] 2b-3).

107 Recanalization (defined as Thrombolysis in Cerebral Infarction [TICI] score 2b-3) a

108 Thrombolysis in cerebral infarction grade 2b and 3 (TICI

109 achieved angiographic reperfusion (score on Thrombolysis in Cerebral Infarction scale of grade 2-3)

110 Substantial reperfusion (modified Thrombolysis in Cerebral Infarction score 2b-3), ambulat

111 sful revascularization defined as a modified Thrombolysis in Cerebral Infarction score of 2b or 3 at

112 ion was defined as a score of 2b or 3 on the Thrombolysis in Cerebral Infarction score.

113 Reperfusion was assessed with angiographic Thrombolysis in Cerebral Infarction scores at the end of

114 Predictive factors of sICH were: thrombolysis in cerebral ischaemia (TICI) score, Alberta

115 SR was defined as modified thrombolysis in cerebral ischemia 2b to 3.

116 ilar in terms of substantial recanalization (Thrombolysis in Cerebral Ischemia scores 2B to 3; drip a

117 The safety of intravenous thrombolysis in ischemic stroke (IS) patients with chron

118 In a 66-patient subgroup with thrombolysis in myocardial infarction </=1 flow, there w

119 utcome was the incidence of no-/slow-reflow (Thrombolysis In Myocardial Infarction </=2).

120 ranch block identified patients with reduced Thrombolysis in Myocardial Infarction (0-2) flow with 70

121 The independent primary end points were thrombolysis in myocardial infarction (TIMI) 3 flow in t

122 d in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 is a ran

123 was major bleeding, defined according to the Thrombolysis in Myocardial Infarction (TIMI) classificat

124 The primary endpoint was thrombolysis in myocardial infarction (TIMI) clinically

125 nt elevation MI within 6 h of symptom onset, Thrombolysis In Myocardial Infarction (TIMI) flow grade

126 nset of symptoms within 12 hours, STEMI, and thrombolysis in myocardial infarction (TIMI) grade 0-1 f

127 (MI), definite stent thrombosis, stroke, or Thrombolysis In Myocardial Infarction (TIMI) major bleed

128 ram, Age, Risk Factors, Troponin (HEART) and Thrombolysis in Myocardial Infarction (TIMI) risk scores

129 after NSTEACS across trials conducted by the Thrombolysis In Myocardial Infarction (TIMI) Study Group

130 immediate stenting (n=73) or DS (n=67) after Thrombolysis In Myocardial Infarction 3 flow restoration

131 in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36) trial and foll

132 ptimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38), which randomi

133 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) demonstrated n

134 or Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial in patie

135 or Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial, compari

136 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a multinat

137 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa

138 evention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 (TRA 2 degrees

139 and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 degrees P

140 and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50) was a multinat

141 Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53).

142 Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53]), alogliptin (

143 mpared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (ticagrelor) w

144 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,

145 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial studied

146 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, which r

147 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54), in which 21,1

148 Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56) investigators

149 apagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) randomized 17

150 apagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) studied the ef

151 apagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58).

152 Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61).

153 ajor bleeding or minor bleeding according to Thrombolysis in Myocardial Infarction [TIMI] criteria or

154 to Open Occluded Coronary Arteries [GUSTO], Thrombolysis in Myocardial Infarction [TIMI], and Acute

155 RS-PR showed higher discriminatory power for thrombolysis in myocardial infarction bleeding than BRS

156 criminatory power of BRS-PR (AUC = 0.809 for thrombolysis in myocardial infarction bleeding; AUC = 0.

157 Thrombolysis In Myocardial Infarction coronary flow grad

158 In a subgroup of patients with thrombolysis in myocardial infarction flow </=1, nitrite

159 Reduced Thrombolysis in Myocardial Infarction flow (0-2) was fou

160 NR was defined as thrombolysis in myocardial infarction flow grade </=2 an

161 ine at admission >132.6 mumol/l (1.5 mg/dl), Thrombolysis In Myocardial Infarction flow grade <3 afte

162 arameters such as blush grade (p = 0.63) and Thrombolysis In Myocardial Infarction flow grade (p = 0.

163 tion, is regularly lysing fibrin and induced Thrombolysis In Myocardial Infarction flow grade 3 paten

164 rhythms (24%), 32% had significantly reduced Thrombolysis in Myocardial Infarction flow.

165 equently used in patients with worse initial thrombolysis in myocardial infarction flow.

166 istically significant reduction in corrected Thrombolysis In Myocardial Infarction frame count more e

167 RRR<=1.7, myocardial perfusion grade<=1, and Thrombolysis in Myocardial Infarction frame count.

168 ded non-coronary artery bypass graft-related Thrombolysis In Myocardial Infarction major and minor bl

169 The CABG-related Thrombolysis In Myocardial Infarction major bleeding was

170 The incidence of Thrombolysis in Myocardial Infarction major or minor ble

171 The primary safety end point was Thrombolysis in Myocardial Infarction major or minor ble

172 The incidence of Thrombolysis in Myocardial Infarction major/minor bleedi

173 or Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction Study 48) was a ra

174 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48) with a f

175 evention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction) (vorapaxar) and P

176 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction) 54 trial randomiz

177 e against 2 validated bleeding scales: TIMI (Thrombolysis In Myocardial Infarction) and GUSTO (Global

178 Symptom-to-reperfusion time, TIMI (Thrombolysis in Myocardial Infarction) blush grade, and

179 ular fibrillation, Killip class >=2 or TIMI (Thrombolysis in Myocardial Infarction) flow <3 after per

180 tom-to-first device time, and baseline TIMI (Thrombolysis In Myocardial Infarction) flow 0/1 versus 2

181 prit, proximal dissection, and initial TIMI (Thrombolysis In Myocardial Infarction) flow grade 0 to 1

182 The principal safety end point was TIMI (Thrombolysis in Myocardial Infarction) major bleeding, w

183 e) and the primary safety endpoint was TIMI (Thrombolysis In Myocardial Infarction) major bleeding.

184 ) severe/life-threatening/moderate and TIMI (Thrombolysis in Myocardial Infarction) major/minor bleed

185 The TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Se

186 When stratified by the TIMI (Thrombolysis in Myocardial Infarction) Risk Score for Se

187 diovascular risk based on the 10-point TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Se

188 Society on Thrombosis and Hemostasis), TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Us

189 leeding defined according to the BARC, TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Ut

190 days after PCI were defined according to the thrombolysis in myocardial infarction, Randomized Evalua

191 ring entire follow-up, while preintervention Thrombolysis in Myocardial Infarction-3 flow was protect

192 cts had an occluded major epicardial artery (thrombolysis in myocardial infarction=0) with ischemic t

193 he subgroup with high thrombus burden (TIMI [Thrombolysis in Myocardial Infarction] thrombus grade >/

194 rtery occlusion as an adjunct to intravenous thrombolysis in patients with acute stroke.

195 is helpful in identifying masses amenable to thrombolysis in patients with prosthetic valve dysfuncti

196 h accuracy and may guide the decision to use thrombolysis in patients with unknown time of stroke ons

197 rrhage within 7 days; Safe Implementation of Thrombolysis in Stroke Monitoring Study's (SITS-MOST) ha

198 the definition by the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), whi

199 l complications associated with tPA-mediated thrombolysis in stroke.

200 Differences in use of thrombolysis in the nine counties of Tyrol in 2010 (rang

201 t include a vascular neurologist can provide thrombolysis in the prehospital setting faster than trea

202 The propagation of thrombolysis in the system without flow was predominantl

203 able for molecular imaging of thrombosis and thrombolysis in vivo and represents a promising candidat

204 red with usual care alone (i.e., intravenous thrombolysis) in the management of acute ischemic stroke

205 as no difference in recanalization (modified Thrombolysis-In-Cerebral-Infarction 2b-3), good clinical

206 to 44 min (29-60) in 2013; symptomatic post-thrombolysis intracerebral haemorrhages occurred in 28 o

207 mic stroke because the risks and benefits of thrombolysis involve deeply personal values.

208 Systemic thrombolysis is a consideration, but its risks of major

209 Thrombolysis is best reserved for severe VTE; inferior v

210 Time to thrombolysis is crucial for outcome in acute ischemic st

211 spatially nonuniform fibrinolytic process in thrombolysis is not currently well understood.

212 Intravenous thrombolysis is the mainstay of acute ischemic stroke ma

213 trolled clinical trial comparing intravenous thrombolysis (IVT) alone with IVT and adjunctive intra-a

214 chemic stroke (AIS) treated with intravenous thrombolysis (IVT) are contradictory, especially when st

215 Intravenous thrombolysis (IVT) followed by mechanical thrombectomy (

216 Intravenous thrombolysis (IVT) for acute ischemic stroke is subject

217 enchymal hematoma (PH) following intravenous thrombolysis (IVT) in ischemic stroke can occur either w

218 a relative contraindication for intravenous thrombolysis (IVT) in patients with acute ischemic strok

219 However, it is not known whether intravenous thrombolysis (IVT) is of added benefit in patients under

220 Whether the time from intravenous thrombolysis (IVT) to endovascular treatment (EVT) in pa

221 ximal intracranial occlusions to intravenous thrombolysis (IVT), led to questions regarding the utili

222 stroke severity, utilization of intravenous thrombolysis (IVT), safety of IVT, and 3-month outcomes.

223 chemic stroke (AIS) treated with intravenous thrombolysis (IVT).

224 Whether bridging therapy (intravenous thrombolysis [IVT] followed by endovascular treatment) i

225 Pharmacomechanical thrombolysis led to more major bleeding events within 10

226 Following embolic stroke, pharmacological thrombolysis limited infarct size, but did not prevent c

227 ntrol for the confounding variables of prior thrombolysis, location of occlusion, and operator expert

228 from stroke recognition to administration of thrombolysis (median, 2.0 vs 1.2 hours; P < .001).

229 lly invasive catheter evacuation followed by thrombolysis (MISTIE), with the aim of decreasing clot s

230 eceive ultrasound-assisted catheter-directed thrombolysis (N = 24) or conventional catheter-directed

231 s (N = 24) or conventional catheter-directed thrombolysis (N = 24).

232 Intra-pump obstruction was treated by thrombolysis (n = 9; success rate, 33%), pump exchange (

233 Older adults regard thrombolysis no less favorably when considering a situat

234 r and molecular mechanisms of thrombosis and thrombolysis of stroke are required.

235 enting as shock or arrest, emergent systemic thrombolysis or embolectomy is reasonable, while for low

236 than 10% of patients require reperfusion by thrombolysis or interventional treatments; those patient

237 stroke), or TIA and who were not undergoing thrombolysis or thrombectomy.

238 with the likelihood of receiving intravenous thrombolysis (OR = 1.42, 95% CI = 0.65-3.10, I(2) = 0%)

239 artery occlusion" OR "retinal ischemia" AND "thrombolysis" OR "fibrinolysis" OR "tissue plasminogen a

240 oke in a trial design allowing thrombectomy, thrombolysis, or both.

241 emic core threshold to predict infarction as thrombolysis patients with complete reperfusion.

242 ed that pharmacomechanical catheter-directed thrombolysis (PCDT) did not prevent postthrombotic syndr

243 (DVT), pharmacomechanical catheter-directed thrombolysis (PCDT) in conjunction with anticoagulation

244 r-directed fibrinolysis, ultrasound-assisted thrombolysis, percutaneous mechanical thrombus fragmenta

245 Thrombolysis, previous ICrH, atrial fibrillation, and ma

246 us Removal with Adjunctive Catheter-Directed Thrombolysis) previously reported that pharmacomechanica

247 lusion, with 59% having received intravenous thrombolysis prior to EVT.

248 on and Dose of r-tPA With the Acoustic Pulse Thrombolysis Procedure for Intermediate-Risk Pulmonary E

249 us Removal With Adjunctive Catheter-Directed Thrombolysis) randomized 692 patients with acute proxima

250 thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesi

251 Our technology demonstrates a thrombolysis rate of 0.7 +/- 0.15 percent mass loss/min

252 Secondary outcomes included thrombolysis rate, secondary intracerebral hemorrhage af

253 Thrombolysis rates in ischemic stroke were 200 of 614 pa

254 Intravenous thrombolysis reduces disability when administered within

255 Thrombolysis regimen (20 mg r-tPA over 15 hours) was ide

256 hrombosis treated with a fixed-dose catheter thrombolysis regimen, the addition of intravascular ultr

257 Thrombolysis-related haemorrhagic transformation (HT) su

258 ematoma expansion and improve the outcome of thrombolysis-related hemorrhage.

259 ost feared complications of the treatment is thrombolysis-related symptomatic intracerebral hemorrhag

260 Intravenous thrombolysis remains the mainstay treatment for acute is

261 However, there are limited data on thrombolysis safety in stroke mimics.

262 Thrombolysis should be considered for patients at low ri

263 djustment for age, stroke severity, sex, and thrombolysis status showed that the distributions of 3-m

264 rom the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED).

265 (Pulmonary Embolism Thrombolysis study [PEITHO]; NCT00639743).

266 t up-to-date literature on imaging, systemic thrombolysis, surgical embolectomy, and catheter-directe

267 Among all patients who received thrombolysis, the proportion of golden hour thrombolysis

268 e not undergoing intravenous or endovascular thrombolysis, the risk of the composite of stroke or dea

269 Primary outcome was alarm-to-thrombolysis time.

270 tion of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lowe

271 ute ischaemia contribute to the prognosis of thrombolysis-treated AIS patients for sICH and mortality

272 cal trials but should probably not be denied thrombolysis treatment on the basis of such a profile al

273 ke onset will result in the highest yield of thrombolysis treatment.

274 The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized (1:1) comparison of

275 used individual patient data from the Stroke Thrombolysis Trialists' (STT) meta-analysis of randomise

276 and those with a contraindication or failed thrombolysis underwent surgery.

277 Patients underwent thrombolysis unless contraindicated, and those with a co

278 ve stroke management programme would improve thrombolysis use and clinical outcome in patients.

279 We focused on thrombolysis use and outcome in the first full 4 years o

280 llowing embolic stroke in male C57bl/6 mice, thrombolysis using tissue-plasminogen activator (t-PA) r

281 er adjuvant intracoronary therapies, such as thrombolysis, vasodilators, glycoprotein IIb/IIIa inhibi

282 thrombolysis, the proportion of golden hour thrombolysis was 6-fold higher after STEMO deployment (6

283 identify patients within the time window of thrombolysis was comparable to multiparametric DWI-FLAIR

284 In conclusion, CA during thrombolysis was impaired in patients who did not respon

285 Using these data, a reduced model of thrombolysis was proposed.

286 Intravenous thrombolysis was safe in this prospective WUS study of p

287 Thrombolysis was started in STEMO if a stroke was confir

288 Older adults were as likely to want stroke thrombolysis when unable to consent (78.1%) as when aske

289 have been devised to capture the benefits of thrombolysis while reducing its risks, but there is limi

290 proportion of patients receiving intravenous thrombolysis with door-to-needle times 45 minutes and 60

291 s, thrombectomy was performed in addition to thrombolysis with intravenous alteplase, but benefits we

292 ective and effective fibrinolytic system for thrombolysis with minimal undesirable side effects.

293 As thrombolysis with recombinant tissue plasminogen activat

294 Intravenous thrombolysis with tenecteplase improves reperfusion prio

295 ) trial was a randomized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normote

296 to the current standard of care: intravenous thrombolysis with tissue-type plasminogen activator and

297 Intravenous thrombolysis with tissue-type plasminogen activator rema

298 st medical management (including intravenous thrombolysis, with rescue thrombectomy for patients with

299 al ischaemic stroke eligible for intravenous thrombolysis within 4.5 h of onset were recruited from T

300 creases the percentage of patients receiving thrombolysis within the golden hour.